Shiga toxin-associated XXXX : absence of recurrence after renal transplantation.

@entity1 @entity3551 @entity6373 @entity1458 @entity11849 @entity205 @entity1381 @entity1141 @entity454
We evaluated the relationship between the acute phase and the development of @entity454 ( @entity454 ) and the outcome of renal transplant in @entity1 with Shiga toxin-associated @entity1381 ( @entity6373 - @entity11849 ). A 20-year retrospective study was performed of 66 renal transplants in 62 @entity1 with @entity6373 - @entity11849 compared with 189 renal allografts in 178 @entity1 with other diseases. Of 62 @entity1 , 61 had >7 days of @entity1458 during the acute phase. @entity6373 - @entity11849 @entity1 survival was not different from controls (92% vs. 83% 15 years after renal transplantation). In the @entity205 (CsA) era, survival of grafts from living related (LRD) and cadaver (CD) donors in @entity6373 - @entity11849 and control @entity1 was 83% versus 70% ( P<0.03) and 77% versus 49% ( P<0.05) at 10 years. Graft survival in @entity6373 - @entity11849 and @entity1141 /obstructive @entity3551 @entity1 was 79% versus 76% ( P=NS), but it was different from that of other diseases (79% vs. 58%, P<0.001). There was no clinical or histopathological evidence of @entity6373 - @entity11849 recurrence. In conclusion, in @entity6373 - @entity11849 @entity1 the duration of the acute oliguric period was a good predictor for the progression to @entity454 . Use of CsA and the absence of recurrence of the disease influenced the excellent prognosis in @entity6373 - @entity11849 @entity1 after renal transplantation. The development of @entity454 in @entity6373 - @entity11849 could be mediated by non-immunological factors.
